These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 30546369)

  • 1. The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment.
    Agresta L; Hoebe KHN; Janssen EM
    Front Immunol; 2018; 9():2809. PubMed ID: 30546369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
    Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Understanding the Roles of CD244 (SLAMF4) in Immune Regulation and Associated Diseases.
    Sun L; Gang X; Li Z; Zhao X; Zhou T; Zhang S; Wang G
    Front Immunol; 2021; 12():648182. PubMed ID: 33841431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tumor cells and tumor microenvironment on NK-cell function.
    Vitale M; Cantoni C; Pietra G; Mingari MC; Moretta L
    Eur J Immunol; 2014 Jun; 44(6):1582-92. PubMed ID: 24777896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMPK activation inhibits the functions of myeloid-derived suppressor cells (MDSC): impact on cancer and aging.
    Salminen A; Kauppinen A; Kaarniranta K
    J Mol Med (Berl); 2019 Aug; 97(8):1049-1064. PubMed ID: 31129755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD244 is expressed on dendritic cells and regulates their functions.
    Georgoudaki AM; Khodabandeh S; Puiac S; Persson CM; Larsson MK; Lind M; Hammarfjord O; Nabatti TH; Wallin RP; Yrlid U; Rhen M; Kumar V; Chambers BJ
    Immunol Cell Biol; 2015 Jul; 93(6):581-90. PubMed ID: 25643613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.
    Lewinsky H; Gunes EG; David K; Radomir L; Kramer MP; Pellegrino B; Perpinial M; Chen J; He TF; Mansour AG; Teng KY; Bhattacharya S; Caserta E; Troadec E; Lee P; Feng M; Keats J; Krishnan A; Rosenzweig M; Yu J; Caligiuri MA; Cohen Y; Shevetz O; Becker-Herman S; Pichiorri F; Rosen S; Shachar I
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33465053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
    Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():398. PubMed ID: 29552012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles.
    Arkhypov I; Lasser S; Petrova V; Weber R; Groth C; Utikal J; Altevogt P; Umansky V
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer.
    Bödder J; Zahan T; van Slooten R; Schreibelt G; de Vries IJM; Flórez-Grau G
    Front Immunol; 2020; 11():631713. PubMed ID: 33679726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomes as mediators of immune regulation and immunotherapy in cancer.
    Kugeratski FG; Kalluri R
    FEBS J; 2021 Jan; 288(1):10-35. PubMed ID: 32910536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy.
    Zalfa C; Paust S
    Front Immunol; 2021; 12():633205. PubMed ID: 34025641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative regulation of myeloid-derived suppressor cells in cancer.
    Qu P; Boelte KC; Lin PC
    Immunol Invest; 2012; 41(6-7):562-80. PubMed ID: 23017135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
    Qu P; Wang LZ; Lin PC
    Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization.
    Groth C; Weber R; Lasser S; Özbay FG; Kurzay A; Petrova V; Altevogt P; Utikal J; Umansky V
    Int J Cancer; 2021 Nov; 149(9):1628-1638. PubMed ID: 34224592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRACC-targeting Fc-fusion protein induces activation of NK cells and DCs and improves T cell immune responses to antigenic targets.
    Aldhamen YA; Rastall DPW; Chen W; Seregin SS; Pereira-Hicks C; Godbehere S; Kaminski NE; Amalfitano A
    Vaccine; 2016 Jun; 34(27):3109-3118. PubMed ID: 27151882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
    Cekic C; Day YJ; Sag D; Linden J
    Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.
    Bruno A; Mortara L; Baci D; Noonan DM; Albini A
    Front Immunol; 2019; 10():771. PubMed ID: 31057536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4).
    Romero X; Benítez D; March S; Vilella R; Miralpeix M; Engel P
    Tissue Antigens; 2004 Aug; 64(2):132-44. PubMed ID: 15245368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.